MedTrace Logo

Dose-finding PKPD Trial for RE02 in Healthy Subjects

NCT05979727 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-11-27

No results posted yet for this study

Summary

The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety \& tolerability of three different doses against a placebo control.

Conditions

  • Healthy

Interventions

DRUG

RE02

Low, medium or high dose of RE02

DRUG

Manitol

Placebo Comparator

Sponsors & Collaborators

  • Reconnect Labs

    lead INDUSTRY

Principal Investigators

  • Erich Seifritz, Prof · University Hospital of Psychiatry Zurich

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2023-12-10
Completion
2023-12-10

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05979727 on ClinicalTrials.gov